% alzhub.org library filter
% Source: https://alzhub.org/research?author=Reyderman+L
% 4 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{mcdade2022-36544184,
  author  = {McDade, E. and Cummings, J. L. and Dhadda, S. and Swanson, C. J. and Reyderman, L. and Kanekiyo, M. and Koyama, A. and Irizarry, M. and others},
  title   = {{Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study}},
  journal = {Alzheimer's research \& therapy},
  year    = {2022},
  doi     = {10.1186/s13195-022-01124-2},
  pmid    = {36544184},
  url     = {https://doi.org/10.1186/s13195-022-01124-2}
}

@article{vandyck2023-22dd8fce,
  author  = {van Dyck, C. H. and Swanson, C. J. and Aisen, P. and Bateman, R. J. and Chen, C. and Gee, M. and Kanekiyo, M. and Li, D. and Reyderman, L. and Cohen, S. and Froelich, L. and Katayama, S. and Sabbagh, M. and Vellas, B. and Watson, D. and Dhadda, S. and Irizarry, M. and Kramer, L. D. and Iwatsubo, T.},
  title   = {{Lecanemab in Early Alzheimer's Disease}},
  journal = {New England Journal of Medicine},
  year    = {2023},
  pmid    = {36449413}
}

@article{honig2023-36949897,
  author  = {Honig, L. S. and Barakos, J. and Dhadda, S. and Kanekiyo, M. and Reyderman, L. and Irizarry, M. and Kramer, L. D. and Swanson, C. J. and others},
  title   = {{ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2023},
  doi     = {10.1002/trc2.12377},
  pmid    = {36949897},
  url     = {https://doi.org/10.1002/trc2.12377}
}

@article{hayato2022-36165093,
  author  = {Hayato, S. and Takenaka, O. and Sreerama Reddy, S. H. and Landry, I. and Reyderman, L. and Koyama, A. and Swanson, C. and Yasuda, S. and others},
  title   = {{Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease}},
  journal = {CPT: pharmacometrics \& systems pharmacology},
  year    = {2022},
  doi     = {10.1002/psp4.12862},
  pmid    = {36165093},
  url     = {https://doi.org/10.1002/psp4.12862}
}